Reported 27 days ago
Moderna's stock fell by 5% in premarket trading following the release of mixed earnings results for the fourth quarter and full year 2024. Although the company reported higher-than-expected revenue of $966 million for Q4, it suffered a larger-than-expected loss of $2.91 per share, compared to Wall Street’s anticipated loss of $2.75. For the year, Moderna generated $3.2 billion in revenue, largely driven by COVID-19 vaccine sales, but faced a $238 million charge related to a manufacturing contract and lower vaccine demand. As the company aims to cut costs and navigate changes in the administration, investors remain cautious about its future performance.
Source: YAHOO